Please use this identifier to cite or link to this item:
Title: Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
Austin Authors: Lewis, Katharine L;Chin, Collin K;Manos, Kate ;Casey, John;Hamad, Nada;Crawford, Julie;Ho, Shir-Jing;Issa, Samar;Grigg, Andrew P ;Wood, Peter;Gandhi, Maher K;Do, Bryan;Nastoupil, Loretta;Hawkes, Eliza A ;Cheah, Chan Y
Affiliation: Department of Haematology, Middlemore Hospital, Auckland, New Zealand
Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia
Medical School, University of Western Australia, Nedlands, WA, Australia
Linear Clinical Research, Nedlands, WA, Australia
Clinical Haematology
Department of Haematology, The Townsville Hospital, Townsville, QLD, Australia
Department of Haematology, St Vincent's Hospital, UNSW, Sydney, NSW, Australia
Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX, USA
University of Melbourne, Melbourne, VIC, Australia
Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia
Department of Haematology, St George Hospital, Sydney, NSW, Australia
Department of Haematology, Eastern Health, Box Hill, VIC, Australia
Department of Haematology, Pathwest Laboratory Medicine, Perth, WA, Australia
Issue Date: Mar-2021 2020-07-16
Publication information: British Journal of Haematology 2020; 192(6): 1049-1053
Abstract: Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encouraging data have emerged from Phase I/II clinical trials treating relapsed/refractory PCNSL/SCNSL with ibrutinib. We analysed 33 patients who received ibrutinib, alone or with other therapies, for PCNSL (n = 9) or SCNSL (n = 24). The objective response rate was 58% (complete response 55%). The median progression-free survival and overall survival for patients with PCNSL were both 3·1 months; for SCNSL, 10·2 and 11·5 months respectively. Only one invasive fungal infection was observed, despite concurrent or recent use of dexamethasone 8-16 mg daily in 14 patients (42%). Ibrutinib has encouraging activity in these aggressive malignancies.
DOI: 10.1111/bjh.16946
ORCID: 0000-0003-0549-5877
PubMed URL: 32677095
Type: Journal Article
Subjects: BTK inhibitor
central nervous system
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.